Tobiloba Oni

Hacking pancreatic cancer and anti-tumor immunity @WhiteheadInst. Valhalla Fellow. @Arsenal FC fanatic.

[Tobiloba Oni @CancerHacker]

Cancer researchers, what's your best take on the definition of cancer? I've been pondering this question and I’d love to hear from others

[Tobiloba Oni @CancerHacker]

@NCICancerBio @BenStanger01 @rkalluriMDPhD @RonDePinho Beyond immunotherapies, it’s exciting to see a surge of preclinical work focused on maximizing the clinical potential of KRAS inhibitors. #PCAMChat24

[Tobiloba Oni @CancerHacker]

@NCICancerBio @BenStanger01 @rkalluriMDPhD @RonDePinho the key questions now are: which immunotherapies synergize best with KRAS inhibitors while minimizing toxicity, and how do different KRAS inhibitors compare in promoting this synergy?

[Anirban Maitra @Aiims1742]

#PCAMChat24 A3: From a clinical/translational standpoint, we finally have drugs that can target KRAS in #PancreaticCancer. This gene is abnormal in >90% of cases, and it has taken four decades since the original discovery tofinally have a slew of drugs in the pipeline that can block aberrant KRAS function in patients. However, we also know that these drugs in and of themselves will not be effective and so a lot of preclinical (a.k.a. laboratory based, in experimental models) studies are ongoing looking at effective combinations that can sustain responses longer in patients, while ameliorating toxicities.

[Tobiloba Oni @CancerHacker]

@NCICancerBio A2: Major breakthroughs in #PancreaticCancer are impossible without fundamental research. We must understand the biological principles that make this disease so aggressive & resistant to most therapies. We can then turn this knowledge into predictive power & effective therapies

[Tobiloba Oni @CancerHacker]

@NCICancerBio @ednacukierman @DelgiornoKathy @CJHPhD @AshleyKiemen @Aiims1742 @KenOliveLab @MaraShermanLab @NinaSteele17 Hi everyone, I'm Tobiloba Oni from @WhiteheadInst. My lab’s mission is to unravel the cellular interaction circuits that drive aggressive biology and immune resistance in #PancreaticCancer. We also develop biologics to target these interactions for effective therapies

[Tobiloba Oni @CancerHacker]

@iaincheeseman Beautiful work, Iain and Jimmy. Love it!

[Anirban Maitra @Aiims1742]

“There are not, and will never be, KRAS inhibitors” 👀
@Pasca_Lab presents a memorable reviewer comment from her 1st unfunded NIH grant at #AACRPan24.
The lesson is that you should not let deflating reviewer comments define the value of your science. Also, persistence!

[Anirban Maitra @Aiims1742]

The company ran a 240 patient (!) randomized phase 2 trial of Simtuzumab in #PancreaticCancer that showed no therapeutic benefit.
https://t.co/FCzUhpDa5V
As an angiogenesis inhibitor (versus the stated inhibition of LOXL2 catalytic activity) this was essentially a rerun of Gem plus Bev trial which had already failed years prior. Really infuriating.

[Tobiloba Oni @CancerHacker]

@raflynn5 @CellCellPress @axe_xie @PeiyuanChai @GarciaLabMS @HSCRB Congrats Ryan!

[Tobiloba Oni @CancerHacker]

@ItaiYanai Well, both camps are right-- and wrong. Life isn’t about isolated parts but about the processes that animate those parts (ie. how those parts dynamically interact). The real debate is actually ancient: Form vs Process (Plato vs. Heraclitus)

[MIT Chemistry @ChemistryMIT]

Glyco enthusiasts from MIT (including Chemistry Professors Laura Kiessling, Barbara Imperiali, and Matt Shoulders) and beyond recently gathered in Bartos Theatre to enjoy presentations of the latest advancements in glycobiology research.

https://t.co/hNRmnxDVh1

[Tobiloba Oni @CancerHacker]

@EmilyAshkin @NIH @theNCI @LabWinslow @JswLab @WhiteheadInst Congrats again Emily! Very well deserved! It’s truly an honor to be part of your incredible journey. Looking forward to the important discoveries we’ll make together

[Semir Beyaz @beyazlab]

I ask for your help to support this Turkey Earthquake Fund https://t.co/Ok9ft2t0TR that will directly help affected families in the region. Thanks everyone who reached out during these difficult times, truly appreciate and will never forget your support ❤️ Please share this 🙏

[Tobiloba Oni @CancerHacker]

@ChrisHeery I think the question was clear enough. I was responding to your comment that “uncontrolled cell division leads to the other aberrations of cancer”. This is not true.

[Tobiloba Oni @CancerHacker]

Cancer researchers, what's your best take on the definition of cancer? I've been pondering this question and I’d love to hear from others

[Tobiloba Oni @CancerHacker]

@ChrisHeery The “it” in my response refers to “uncontrolled cell division”, not “cancer”

[Tobiloba Oni @CancerHacker]

@ChrisHeery Excuse my ambiguity. I meant proliferation is one of the consequences of cancer, not the driving force

[Tobiloba Oni @CancerHacker]

@ChrisHeery I don’t think uncontrolled cell division is the causal agent and defining factor of cancer. Rather, it’s a consequence of malignant transformation and, unfortunately, the predominant focus of research and clinical efforts. We need to rethink cancer.

[Tobiloba Oni @CancerHacker]

For anyone interested, I also asked ChatGPT

[Tobiloba Oni @CancerHacker]

Surely cancer is not just a disease of uncontrolled cell division. This does not explain malignant behaviors such as metastasis and dormancy

[Chris Tape @christophertape]

@anideshpandelab @CancerHacker Agreed. I’ve always thought that cancer is when cellular fitness becomes dominant over organismal fitness.